Dose-dependent activation of distinct hypertrophic pathways by serotonin in cardiac cells

1 Institut National de la Santé et de la Recherche Médicale, U858, and 2 Université de Toulouse, UPS, Institut de Médecine Moléculaire de Rangueil, Centre Hospitalier Universitaire de Toulouse, IFR31, Toulouse, France Submitted 9 April 2009 ; accepted in final form 18 June 2009 There is substantial...

Ausführliche Beschreibung

Gespeichert in:
Bibliographische Detailangaben
Veröffentlicht in:American journal of physiology. Heart and circulatory physiology 2009-08, Vol.297 (2), p.H821-H828
Hauptverfasser: Villeneuve, C, Caudrillier, A, Ordener, C, Pizzinat, N, Parini, A, Mialet-Perez, J
Format: Artikel
Sprache:eng
Schlagworte:
Online-Zugang:Volltext
Tags: Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
Beschreibung
Zusammenfassung:1 Institut National de la Santé et de la Recherche Médicale, U858, and 2 Université de Toulouse, UPS, Institut de Médecine Moléculaire de Rangueil, Centre Hospitalier Universitaire de Toulouse, IFR31, Toulouse, France Submitted 9 April 2009 ; accepted in final form 18 June 2009 There is substantial evidence supporting a hypertrophic action of serotonin [5-hydroxytryptamine (5-HT)] in cardiomyocytes. However, little is known about the mechanisms involved. We previously demonstrated that 5-HT-induced hypertrophy depends, in part, on the generation of reactive oxygen species by monoamine oxidase-A (MAO-A) (see Ref. 3). Cardiomyocytes express 5-HT 2 receptors, which may also participate in hypertrophy. Here, we analyzed the respective contribution of 5-HT 2 receptors and MAO-A in H9C2 cardiomyoblast hypertrophy. 5-HT induced a dose-dependent increase in [ 3 H]leucine incorporation and stimulation of two markers of cardiac hypertrophy, ANF-luc and SK-actin-luc reporter genes. Experiments using 1 µM 5-HT showed that hypertrophic response occurred independently from MAO-A. Using pharmacological inhibitors (M100907 and ketanserin), we identified a novel mechanism of action involving 5-HT 2A receptors and requiring Ca 2+ /calcineurin/nuclear factor of activated T-cell activation. The activation of this hypertrophic pathway was fully prevented by 5-HT 2A inhibitors and was unaffected by MAO inhibition. When 10 µM 5-HT was used, an additional hypertrophic response, prevented by the MAO inhibitors pargyline and RO 41-1049, was observed. Unlike the 5-HT 2A -receptor-mediated H9C2 cell hypertrophy, MAO-A-dependent hypertrophic response required activation of extracellular-regulated kinases. In conclusion, our results show the existence of a dose-dependent shift of activation of distinct intracellular pathways involved in 5-HT-mediated hypertrophy of cardiac cells. 5-hydroxytryptamine; 5-hydroxytryptamine 2A; monoamine oxidase type A; hypertrophy Address for reprint requests and other correspondence: J. Mialet-Perez, INSERM U858, BP 84225, 31432 Toulouse Cedex 4, France (E-mail: jeanne.perez{at}inserm.fr )
ISSN:0363-6135
1522-1539
DOI:10.1152/ajpheart.00345.2009